LACTOLOGY FOUNDATION

Docusate sodium (ATC A06AA02) is a synthetic stool softener from the group of emollient laxatives, generally considered compatible with use in pregnancy and breastfeeding when used in recommended doses and for short periods.medpedia.framar+3

Monograph header

Title: Docusate sodium – toxicological‑lactological monograph (ATC A06AA02)

ATC class A06AA02 belongs to the subgroup of stool softeners/emollient laxatives used for the symptomatic treatment of constipation and difficult defecation. Docusate sodium is the sodium salt of bis(2‑ethylhexyl) sulfosuccinate (dioctyl sulfosuccinate, DOSS), an anionic surfactant that acts locally in the intestinal lumen.atcddd.fhi+4

Pharmacology and mechanism of action

Docusate sodium is an anionic wetting agent and faecal softener that lowers the surface tension of intestinal contents and promotes penetration of water and lipids into hardened stool. This leads to hydration and softening of faecal masses, facilitating defecation without significant stimulation of propulsive motility when used at usual doses.pubchem.ncbi.nlm.nih+4

Onset of laxative effect is usually within 1–2 days after oral administration. Systemic absorption from the gastrointestinal tract appears minimal at therapeutic doses, and the primary site of action is intraluminal rather than systemic.list.essentialmeds+3

Indications and dosing (general)

Main indications for docusate sodium are:

·        Symptomatic treatment of constipation, including chronic constipation and opioid‑induced constipation.medpedia.framar+1

·        Situations with painful or difficult defecation where straining should be minimized (e.g. after anorectal surgery, hemorrhoids; according to general laxative practice, not always in product labels).mothertobaby+1

Typical oral adult doses in available products are in the range of 50–300 mg/day, divided, with effect expected within 1–2 days. For liquid oral preparations, summary of product characteristics document daily doses up to 50 ml, with higher initial doses progressively reduced as constipation improves. Docusate sodium is commonly available without prescription in many countries, reflecting its use as an over‑the‑counter stool softener.typharm+3

Contraindications and precautions

Docusate sodium should not be used in patients with acute obstructive gastrointestinal diseases such as intestinal ileus, acute surgical abdomen or suspected appendicitis. It is also contraindicated when there is unexplained abdominal pain, nausea, or vomiting that may signal serious pathology, in line with general laxative safety recommendations.mothertobaby+1

Prolonged or excessive use can cause severe diarrhea, dehydration and disturbances in electrolyte balance, therefore therapy should be limited to the shortest duration necessary to restore bowel function. In some regulatory documents, excretion in breast milk is mentioned and use with caution in lactating women is advised, especially at high doses or prolonged courses.sps+3

Adverse effects and toxicity

Common adverse effects of docusate sodium include abdominal pain or cramps, mild gastrointestinal discomfort, and diarrhea. Excessive diarrhea may result in dehydration and electrolyte imbalance, particularly in vulnerable patients (elderly, children, patients with comorbidities).typharm+3

Hypersensitivity reactions (skin rash, pruritus) have been reported but appear uncommon. Overall toxicity at recommended doses is low, and serious adverse events are rare when treatment is short‑term and monitored.list.essentialmeds+2

A single case report described neonatal hypomagnesemia associated with maternal use of excessive docusate sodium during pregnancy, suggesting that very high or prolonged dosing may carry risk for electrolyte disturbances in the newborn. This appears exceptional rather than typical for standard dosing.mothertobaby

Use in pregnancy

Available clinical and observational data do not show an increased risk of congenital malformations or adverse pregnancy outcomes when docusate sodium is used at recommended doses. MotherToBaby and other teratology information services report that short‑term use in pregnancy is unlikely to cause problems such as preterm delivery or low birth weight.nhs+3

National health services and pregnancy medicine information sources state that docusate is occasionally used during pregnancy and that there is no evidence of harm to the fetus, but other laxatives such as polyethylene glycol or bulk‑forming agents are generally preferred because they have more extensive safety data. When dietary and lifestyle measures fail, docusate sodium may be considered as an option, usually for short‑term symptom relief.droracle+3

From a toxicological perspective, the low systemic absorption and predominantly local action in the gut support a low teratogenic potential, although absence of strong systemic exposure does not completely exclude risk. The main practical recommendation is to avoid prolonged or high‑dose use in pregnancy and to respect product labeling and obstetric guidance.mothertobaby+3

Use in lactation

Direct studies measuring docusate concentrations in human breast milk are limited, but pharmacokinetic data and expert reviews indicate minimal transfer into milk at therapeutic doses. Some product information acknowledges that docusate sodium can be excreted in breast milk and recommends cautious use in lactating mothers.nhs+4

Specialist pharmacy services and national advisory bodies state that docusate can be used during breastfeeding and that any amount entering breast milk is likely to be very small and not expected to cause adverse effects in the nursing infant. Occasional reports of loose stools in breastfed infants exist for laxatives in general, but robust evidence of clinically significant toxicity from maternal docusate exposure is lacking.droracle+3

From a lactological standpoint, docusate sodium is generally classified as compatible with breastfeeding when used in recommended doses for short periods, with preference still often given to non‑absorbed laxatives such as polyethylene glycol or lactulose as first‑line choices. Monitoring of infant stool pattern may be considered in cases of prolonged maternal use or high doses.sps+2

Comparative lactation safety within stool softeners

Within emollient laxatives, non‑absorbed or minimally absorbed agents are generally preferred for breastfeeding women, which includes docusate sodium but not necessarily mineral oil at high doses or prolonged use. This positioning is relevant in toxicological‑lactological classification of the A06AA subgroup.atcddd.fhi+4

Toxicological‑lactological classification summary (A06AA02)

·        Toxicological profile at therapeutic doses: low systemic toxicity, main risks related to overuse leading to diarrhea, dehydration, and electrolyte disturbance.medpedia.framar+3

·        Pregnancy: compatible for short‑term use when needed; not associated with increased risk of malformations or major adverse outcomes at recommended doses; preferably second‑line after non‑pharmacological measures and better‑studied laxatives.medicinesinpregnancy+4

·        Lactation: generally compatible; minimal expected infant exposure; alternative non‑absorbed laxatives may be preferred but docusate sodium is acceptable when clinically indicated.mothertobaby+4

·        Overall toxicological‑lactological rating: low‑risk stool softener when used short‑term in approved doses, with caution against chronic or excessive use and attention to hydration and electrolyte status.list.essentialmeds+3